JP2024516320A - Ｆｃ受容体への結合が改変されたＦｃ変異体 - Google Patents

Ｆｃ受容体への結合が改変されたＦｃ変異体 Download PDF

Info

Publication number
JP2024516320A
JP2024516320A JP2023568549A JP2023568549A JP2024516320A JP 2024516320 A JP2024516320 A JP 2024516320A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2024516320 A JP2024516320 A JP 2024516320A
Authority
JP
Japan
Prior art keywords
seq
sequence
set forth
index
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516320A5 (https=
Inventor
フォンケン フー
ショアイシアン チョウ
チーハイ ウー
Original Assignee
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス（スーチョウ）カンパニー，リミティド filed Critical イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Publication of JP2024516320A publication Critical patent/JP2024516320A/ja
Publication of JP2024516320A5 publication Critical patent/JP2024516320A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023568549A 2021-05-07 2022-05-06 Ｆｃ受容体への結合が改変されたＦｃ変異体 Pending JP2024516320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (2)

Publication Number Publication Date
JP2024516320A true JP2024516320A (ja) 2024-04-12
JP2024516320A5 JP2024516320A5 (https=) 2025-05-12

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568549A Pending JP2024516320A (ja) 2021-05-07 2022-05-06 Ｆｃ受容体への結合が改変されたＦｃ変異体

Country Status (8)

Country Link
US (1) US20240228579A1 (https=)
EP (1) EP4335868A4 (https=)
JP (1) JP2024516320A (https=)
CN (1) CN117295760A (https=)
AU (1) AU2022269145A1 (https=)
CA (1) CA3218187A1 (https=)
TW (1) TWI839729B (https=)
WO (1) WO2022233320A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712795A (zh) * 2023-08-30 2026-03-20 安斯泰来制药株式会社 Fc区改造体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2019502698A (ja) * 2015-12-17 2019-01-31 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2019502698A (ja) * 2015-12-17 2019-01-31 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用

Also Published As

Publication number Publication date
EP4335868A1 (en) 2024-03-13
EP4335868A4 (en) 2025-08-13
US20240228579A1 (en) 2024-07-11
CN117295760A (zh) 2023-12-26
WO2022233320A1 (zh) 2022-11-10
TW202246313A (zh) 2022-12-01
TWI839729B (zh) 2024-04-21
CA3218187A1 (en) 2022-11-10
AU2022269145A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CN113817049B (zh) 修饰的Fc片段在免疫疗法中的应用
CN116041516A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP7264381B2 (ja) 血中半減期の向上のための抗体Ｆｃ変異体
KR20140014061A (ko) 항-huTNFR1 항체
JP2012515556A5 (https=)
CN111601821B (zh) 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
AU2022404170A1 (en) Bispecific antibody and use thereof
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
JP2025517120A (ja) アルブミン結合ポリペプチド及びその使用
TWI839729B (zh) 與Fc受體結合改變的Fc突變體
JP2024534034A (ja) 抗ｖｅｇｆｒ１抗体及びそれらの使用
CN115175736A (zh) 杂交抗体
CN116783220A (zh) 抗bcma抗体及其制备方法和应用
CN120590537A (zh) 靶向tigit的双特异性抗体
JP2025519559A (ja) ＦｃＲｎ結合ポリペプチド及びその使用
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
KR20250139314A (ko) 안티-pdl1 단일 도메인 항체, 융합 단백질 및 이의 용도
KR20260007638A (ko) Cd3을 표적으로 하는 항체 또는 이의 항원 결합 단편 및 이의 용도
HK40061359A (en) Antibodies targeting c5ar
TW202241957A (zh) 抗ｐｄ－１抗體及其用途
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
WO2026057033A1 (zh) 结合tl1a的抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203